This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Role of Bruton’s tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
Blood Cancer Journal Open Access 01 August 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.
Shah JJ, Orlowski RZ . Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009; 23: 1964–1979.
Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther 2013; e-pub ahead of print 27 March 2013; doi:10.1158/1535-7163.MCT-12-1151.
Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest 2004; 113: 1763–1773.
Boylan KL, Gosse MA, Staggs SE, Janz S, Grindle S, Kansas GS et al. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma. Cancer Res 2007; 67: 4069–4078.
Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007; 109: 2708–2717.
Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007; 109: 3177–3188.
Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3. Blood 2011; 118: 3512–3524.
Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B et al. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 2013; 27: 226–232.
Kunkel EJ, Butcher EC . Plasma-cell homing. Nat Rev Immunol 2003; 3: 822–829.
Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341–4351.
Moriuchi M, Ohmachi K, Kojima M, Tsuboi K, Ogawa Y, Nakamura N et al. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses. Tokai J Exp Clin Med 2010; 35: 17–20.
Peceliunas V, Janiulioniene A, Matuzeviciene R, Zvirblis T, Griskevicius L . Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma 2012; 53: 641–647.
Mo SL, Li J, Loh YS, Brown RD, Smith AL, Chen Y et al. Factors influencing the abundance of the side population in a human myeloma cell line. Bone Marrow Res 2011; 2011: 524845.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
BVN receives research support from Millennium Pharmaceuticals Inc., Cambridge, MA. The other authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Stessman, H., Mansoor, A., Zhan, F. et al. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia 27, 2075–2077 (2013). https://doi.org/10.1038/leu.2013.148
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.148
This article is cited by
-
Prognostic significance of 68Ga-Pentixafor PET/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET/CT and laboratory results
Annals of Nuclear Medicine (2021)
-
Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT
European Journal of Nuclear Medicine and Molecular Imaging (2020)
-
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
International Journal of Hematology (2017)
-
Role of Bruton’s tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
Blood Cancer Journal (2014)
-
High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma
Leukemia (2014)